NCT06947993From ClinicalTrials.govRecruiting

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

At a glance

Phase: Phase 2
Study type: Interventional
Sponsor: Novartis Pharmaceuticals
Enrolment target: 224
Started: 16 May 2025
Main results due: 27 November 2028
Study sites: 105
Registry updated: 28 September 2026

Can you take part?

Ages 18 years to 100 years.
Open to any sex.
You need the condition being studied — healthy volunteers are not accepted.

These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.

Read the full eligibility criteria

Key Inclusion Criteria of the master protocol:

* Able and willing to sign the informed consent (IC)
* Patients with a diagnosis of AD and onset of disease for at least 1 year
* Moderate to severe AD

Key Exclusion Criteria of the master protocol:

* Participants with a clinically significant medical condition or infectious disease (specified in sub-protocol)
* Participants with clinically significant abnormal hematology, clinical chemistry, or urine test results or clinically significant abnormal ECG
* Participant with any other active inflammatory skin disease
* Participants with any chronic, uncontrolled medical condition, which would put the participant at increased risk during the study (e.g., uncontrolled: diabetes, hypertension)
* Participants with any clinically unstable disease states that would likely require systemic corticosteroids (e.g., uncontrolled asthma)

Additional inclusion and exclusion criteria may apply depending on the intervention specific requirements

What this study is about

In the sponsor’s own words, from the registry.

This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).

Study sites(105)

Novartis Investigative Site
Birmingham, Alabama, United States
Recruiting
Novartis Investigative Site
Birmingham, Alabama, United States
Recruiting
Novartis Investigative Site
Fort Smith, Arkansas, United States
Recruiting
Novartis Investigative Site
Fountain Valley, California, United States
Recruiting
Novartis Investigative Site
Los Angeles, California, United States
Recruiting
Novartis Investigative Site
Sacramento, California, United States
Recruiting
Novartis Investigative Site
Santa Ana, California, United States
Recruiting
Novartis Investigative Site
Santa Monica, California, United States
Recruiting
Novartis Investigative Site
Washington D.C., District of Columbia, United States
Recruiting
Novartis Investigative Site
Miami, Florida, United States
Recruiting
Novartis Investigative Site
St. Petersburg, Florida, United States
Recruiting
Novartis Investigative Site
Atlanta, Georgia, United States
Recruiting
Novartis Investigative Site
Macon, Georgia, United States
Recruiting
Novartis Investigative Site
Louisville, Kentucky, United States
Recruiting
Novartis Investigative Site
Brighton, Massachusetts, United States
Recruiting
Novartis Investigative Site
Troy, Michigan, United States
Recruiting
Novartis Investigative Site
Saint Joseph, Missouri, United States
Recruiting
Novartis Investigative Site
Portsmouth, New Hampshire, United States
Recruiting
Novartis Investigative Site
Brooklyn, New York, United States
Recruiting
Novartis Investigative Site
Arlington, Texas, United States
Recruiting
Novartis Investigative Site
Cypress, Texas, United States
Recruiting
Novartis Investigative Site
Dallas, Texas, United States
Recruiting
Novartis Investigative Site
Houston, Texas, United States
Recruiting
Novartis Investigative Site
San Antonio, Texas, United States
Recruiting
Novartis Investigative Site
Caba, Buenos Aires, Argentina
Recruiting
Novartis Investigative Site
Caba, Buenos Aires, Argentina
Recruiting
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
Recruiting
Novartis Investigative Site
Edmonton, Alberta, Canada
Active, not recruiting
Novartis Investigative Site
Hamilton, Ontario, Canada
Recruiting
Novartis Investigative Site
Markham, Ontario, Canada
Recruiting
Novartis Investigative Site
Montreal, Quebec, Canada
Recruiting
Novartis Investigative Site
Verdun, Quebec, Canada
Active, not recruiting
Novartis Investigative Site
Guangzhou, Guangdong, China
Active, not recruiting
Novartis Investigative Site
Shantou, Guangdong, China
Active, not recruiting
Novartis Investigative Site
Changsha, Hunan, China
Active, not recruiting
Novartis Investigative Site
Changchun, Jilin, China
Active, not recruiting
Novartis Investigative Site
Hangzhou, Zhejiang, China
Recruiting
Novartis Investigative Site
Beijing, China
Withdrawn
Novartis Investigative Site
Beijing, China
Active, not recruiting
Novartis Investigative Site
Shanghai, China
Recruiting
Novartis Investigative Site
Plzen Bory, Czechia
Recruiting
Novartis Investigative Site
Prague, Czechia
Recruiting
Novartis Investigative Site
Prague, Czechia
Recruiting
Novartis Investigative Site
Prague, Czechia
Recruiting
Novartis Investigative Site
Prague, Czechia
Recruiting
Novartis Investigative Site
Brest, France
Recruiting
Novartis Investigative Site
Lille, France
Recruiting
Novartis Investigative Site
Lorient, France
Recruiting
Novartis Investigative Site
Paris, France
Recruiting
Novartis Investigative Site
Pierre-Bénite, France
Recruiting
Novartis Investigative Site
Reims, France
Recruiting
Novartis Investigative Site
Rouen, France
Recruiting
Novartis Investigative Site
Frankfurt am Main, Hesse, Germany
Active, not recruiting
Novartis Investigative Site
Mainz, Rhineland-Palatinate, Germany
Active, not recruiting
Novartis Investigative Site
Bad Bentheim, Germany
Active, not recruiting
Novartis Investigative Site
Dresden, Germany
Active, not recruiting
Novartis Investigative Site
Hamburg, Germany
Recruiting
Novartis Investigative Site
Heidelberg, Germany
Active, not recruiting
Novartis Investigative Site
Magdeburg, Germany
Active, not recruiting
Novartis Investigative Site
Münster, Germany
Active, not recruiting

Showing 60 of 105 sites — filter to narrow it down. 69 of the 105 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.

Source: ClinicalTrials.gov record NCT06947993. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Not the right study?

Answer three questions and see the studies recruiting near you, in plain language.

Find a study for me